Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT01392235
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China
Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT01301911
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT01270386
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China
A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 121
- Registration Number
- NCT01192971
- Locations
- 🇨🇳
Nanjing Millitary Eighty-one Hosiptal, Nanjing, Jiangsu, China
© Copyright 2024. All Rights Reserved by MedPath